The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1168
October 27, 2003
View Complete Issue         Table of Contents 2019 
Iodine-131 Tositumomab (Bexxar) for Treatment of Lymphoma
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Iodine-131 Tositumomab (Bexxar) for Treatment of Lymphoma
October 27, 2003 (Issue: 1168)
Bexxar, a combination of the monoclonal antibody tositumomab and radiolabeled Iodine-131 tositumomab (Corixa Corp/GlaxoSmithKline) has been approved by the FDA for a single treatment of relapsed follicular non-Hodgkin's lymphoma (NHL) in patients who...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Iodine-131 Tositumomab (Bexxar) for Treatment of Lymphoma
Article code: 1168b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.